Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS)

Semanteon Capital Management LP purchased a new position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 56,313 shares of the company's stock, valued at approximately $912,000. Semanteon Capital Management LP owned about 0.09% of Evolus at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Quest Partners LLC bought a new position in Evolus in the 2nd quarter valued at $43,000. Quarry LP bought a new position in Evolus in the 2nd quarter valued at $54,000. Profund Advisors LLC bought a new position in Evolus in the 2nd quarter valued at $130,000. Arizona State Retirement System boosted its position in Evolus by 9.4% in the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock valued at $158,000 after buying an additional 1,253 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Evolus by 9.9% in the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company's stock valued at $162,000 after buying an additional 1,035 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on EOLS. Barclays increased their price objective on Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, October 3rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Sandra Beaver sold 3,276 shares of the firm's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Evolus Trading Down 1.2 %

Shares of NASDAQ:EOLS traded down $0.19 during midday trading on Monday, hitting $16.27. The company had a trading volume of 358,116 shares, compared to its average volume of 583,198. Evolus, Inc. has a 12 month low of $7.44 and a 12 month high of $17.82. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -15.50 and a beta of 1.31. The firm has a fifty day simple moving average of $16.15 and a 200 day simple moving average of $13.60.

Evolus (NASDAQ:EOLS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, analysts predict that Evolus, Inc. will post -0.64 EPS for the current year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.